Artículos relacionados
![](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/thumbnail/S0001731024000243:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9/t1/zx4Q/XH5Tma1a/6fSs=)
Área salud
[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review
marzo 18, 2024
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 115. Núm. 3. (Marzo 2024)
Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. In dermatology, topical roflumilast is authorized by the US Food and Drug Administration for the […]
![](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/thumbnail/S000173102300738X:fx1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9/t1/zx4Q/XH5Tma1a/6fSs=)
Área salud
[Translated article] What Proportion of the Spanish Dermatology Caseload Corresponds to Pediatric Dermatoses? Results From the DIADERM National Random Sampling Survey
enero 15, 2024
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 114. Núm. 10. (Noviembre - Diciembre 2023)
Background Visits for skin conditions are very common in pediatric primary care, and many of the patients seen in outpatient dermatology clinics are children or adolescents. Little, however, has been published about the true prevalence […]